TY - JOUR
T1 - Aptamers and their applications in nanomedicine
AU - Sun, Hongguang
AU - Zu, Youli
N1 - Publisher Copyright:
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015/5/27
Y1 - 2015/5/27
N2 - Aptamers are composed of short RNA or single-stranded DNA sequences that, when folded into their unique 3D conformation, can bind to their targets with high specificity and affinity. Although functionally similar to protein antibodies, oligonucleotide aptamers offer several advantages over protein antibodies in biomedical and clinical applications. Through the enhanced permeability and retention effect, nanomedicines can improve the therapeutic index of a treatment and reduce side effects by enhancing accumulation at the disease site. However, this targets tumors passively and, thus, may not be ideal for targeted therapy. To construct ligand-directed "active targeting" nanobased delivery systems, aptamer-equipped nanomedicines have been tested for in vitro diagnosis, in vivo imaging, targeted cancer therapy, theranostic approaches, sub-cellular molecule detection, food safety, and environmental monitoring. This review focuses on the development of aptamer-conjugated nanomedicines and their application for in vivo imaging, targeted therapy, and theranostics.
AB - Aptamers are composed of short RNA or single-stranded DNA sequences that, when folded into their unique 3D conformation, can bind to their targets with high specificity and affinity. Although functionally similar to protein antibodies, oligonucleotide aptamers offer several advantages over protein antibodies in biomedical and clinical applications. Through the enhanced permeability and retention effect, nanomedicines can improve the therapeutic index of a treatment and reduce side effects by enhancing accumulation at the disease site. However, this targets tumors passively and, thus, may not be ideal for targeted therapy. To construct ligand-directed "active targeting" nanobased delivery systems, aptamer-equipped nanomedicines have been tested for in vitro diagnosis, in vivo imaging, targeted cancer therapy, theranostic approaches, sub-cellular molecule detection, food safety, and environmental monitoring. This review focuses on the development of aptamer-conjugated nanomedicines and their application for in vivo imaging, targeted therapy, and theranostics.
KW - active targeting
KW - aptamers
KW - combinational therapy
KW - nanomedicine
KW - on-command release system
UR - http://www.scopus.com/inward/record.url?scp=84923174595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923174595&partnerID=8YFLogxK
U2 - 10.1002/smll.201403073
DO - 10.1002/smll.201403073
M3 - Article
C2 - 25677591
AN - SCOPUS:84923174595
VL - 11
SP - 2352
EP - 2364
JO - Small
JF - Small
SN - 1613-6810
IS - 20
ER -